SAN DIEGO, April 5, 2011 /PRNewswire/ -- Ridge Diagnostics, Inc., a neurodiagnostic company, announced that the Scientific Program Committee of the American Psychiatric Association has accepted for presentation their scientific and clinical report entitled, "Assessment of a Biomarker Panel for Major Depressive Disorder in a Community Based Study".  

The presentation will be made by Dr. Perry Renshaw, Director of Magnetic Resonance, Utah Brain Institute, Professor of Psychiatry, University of Utah School of Medicine, Salt Lake City, UT.  

A blood test, for the first time, provides clinicians with biological information derived from physiological changes associated with MDD.  By adding an objective, biological basis, the blood test results are intended to augment the current tools used for neuropsychiatric diagnosis and patient management.  

"The data being presented a the APA meeting validates the clinical importance of the MDDScore™ in community-based psychiatric practices," stated Lonna J. Williams, CEO of Ridge Diagnostics.  "The outcomes prove that accurate diagnosis can be difficult, even in psychiatric practices, and that patients both desire and respond to blood tests for mental health purposes as they are accustomed to blood tests for their medical care."  

Dr. Renshaw will present the information at the APA Annual Meeting in Honolulu, HI, May 14-18, 2011.

Ridge Diagnostics, Inc. Ridge Diagnostics is a neurodiagnostic company developing and marketing blood-based tests to diagnose and monitor neuropsychiatric disorders.  Ridge has commercialized the first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD).  The portfolio of neurodiagnostic blood tests are based on a proprietary Human Biomarker Library and Hyper-Mapping technology.  The testing services are provided by the Ridge owned CLIA laboratory.  The company is located in San Diego, CA and Research Triangle Park, NC.  www.ridgedx.com

SOURCE Ridge Diagnostics, Inc.